Close Menu

NEW YORK – ERS Genomics said on Thursday that it has signed a licensing agreement granting discovery biology company Axxam access to ERS' CRISPR-Cas9 patent portfolio, to support Axxam's integrated discovery service platform.

Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.